Economic Burden of Generalized Pustular Psoriasis: A Population-based Register Study in Finland
Authors:
Open Access
- 10 February 2026
- journal article
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106, adv44671
Abstract
Generalized pustular psoriasis is an inflammatory disease characterized by potentially life-threatening flares. This study assessed the economic burden of generalized pustular psoriasis in Finland by comparing healthcare resource utilization and both direct and indirect costs to population-based and psoriasis vulgaris control groups and between generalized pustular psoriasis patients with and without flares. Patients with ≥ 2 generalized pustular psoriasis diagnoses (ICD-10: L40.1) at a dermatology clinic in secondary healthcare and matched controls were identified during 1996–2019 from national registers. Direct costs were based on primary and secondary healthcare resource utilization and medications, and indirect costs on productivity loss due to sick leaves, disability pensions, and rehabilitation periods. All-cause annual direct costs were 3-fold higher in generalized pustular psoriasis (mean: €10,323) compared with population-based (€3,345; p < 0.001), and psoriasis vulgaris controls (€3,569; p < 0.001). Having flares was associated with 2.7-fold higher direct costs compared with no flares (cost ratio 2.7; 95% CI, 2.1–3.5; p < 0.001), driven by higher hospitalization rates of patients with flares. Flares were also associated with 2.5-fold higher indirect costs (cost ratio 2.5; 95% CI, 1.6–4.0; p < 0.001) compared with no flares. This first comprehensive economic evaluation of generalized pustular psoriasis highlights the substantial economic impact, in particular in patients with flares, and emphasizes costs due to work disability.Keywords
This publication has 35 references indexed in Scilit:
- Prevalence and incidence of patients with generalized pustular psoriasis in Denmark—A nationwide registry‐based studyJEADV Clinical Practice, 2023
- Mortality in generalized pustular psoriasis: A population-based national register studyJournal of the American Academy of Dermatology, 2023
- Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 studyJournal of the American Academy of Dermatology, 2023
- Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health RecordsJAMA Dermatology, 2022
- Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in JapanJournal of the American Academy of Dermatology, 2022
- Clinical Course and Characteristics of Generalized Pustular PsoriasisAmerican Journal of Clinical Dermatology, 2022
- Treatment Options and Goals for Patients with Generalized Pustular PsoriasisAmerican Journal of Clinical Dermatology, 2022
- Diagnosis of Generalized Pustular PsoriasisAmerican Journal of Clinical Dermatology, 2022
- Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory AspectsAmerican Journal of Clinical Dermatology, 2019
- Return to Work After Temporary Disability Pension in FinlandJournal of Occupational Rehabilitation, 2014